Echo is initiating the program based upon positive results seen in ex-vivo testing on humans undergoing exercise, using a needle-free continuous lactate monitoring biosensor, as lactate monitoring is important in critically ill patients in shock as the amount of lactate produced is believed to correlate with oxygen deprivation, hypoperfusion and the severity of shock.

Echo Therapeutics board CEO, president and chairman Patrick Mooney said that they are excited to begin yet another transdermal, continuous monitoring program, this one in lactate biosensing. The initiation of this program demonstrates the robust platform our technology provides, extending well beyond the hospital and diabetes markets.

“The results of our ex-vivo testing strongly suggest that we can effectively monitor lactate thresholds using our transdermal biosensor technology,” Mooney said.

“Leveraging our deep expertise in advanced skin permeation technology, we anticipate commencing additional programs over the coming year, building a significant pipeline of both transdermal biosensors and needle-free topical and systemic drug delivery products.”

Echo is a developer of needle-free Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude SkinPrep System for transdermal drug delivery.